Nadine M Tung

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7861814/publications.pdf

Version: 2024-02-01

		31976	17592
150	15,872	53	121
papers	citations	h-index	g-index

154	154	154	17571
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Targeted BRCA1/2 population screening among Ashkenazi Jewish individuals using a web-enabled medical model: An observational cohort study. Genetics in Medicine, 2022, 24, 564-575.	2.4	8
2	Q and A: A New Standard of Care for Germline BRCA1 and/or BRCA2 Mutation Carriers With Early-Stage Breast Cancer. JCO Oncology Practice, 2022, 18, 427-429.	2.9	1
3	Polygenic risk modeling for prediction of epithelial ovarian cancer risk. European Journal of Human Genetics, 2022, 30, 349-362.	2.8	23
4	Contraceptive use and the risk of ovarian cancer among women with a BRCA1 or BRCA2 mutation. Gynecologic Oncology, 2022, 164, 514-521.	1.4	8
5	The risks of breast and ovarian cancer associated with the Ashkenazi Jewish founder allele <scp>BRCA2 6174delT</scp>. Clinical Genetics, 2022, 101, 317-323.	2.0	0
6	Abstract OT2-18-01: Harnessing olaparib, palbociclib, and endocrine therapy (HOPE): Phase I/II trial of olaparib, palbociclib and fulvestrant in patients with BRCA1/2-associated, hormone receptor-positive, HER2-negative metastatic breast cancer. Cancer Research, 2022, 82, OT2-18-01-OT2-18-01.	0.9	1
7	Abstract P3-18-05: Impact of neoadjuvant paclitaxel/trastuzumab/pertuzumab (THP) on breast tumor downsizing for patients with HER2+ breast cancer - results from a single-arm clinical trial. Cancer Research, 2022, 82, P3-18-05-P3-18-05.	0.9	0
8	Abstract P2-14-18: A randomized phase II trial of carboplatin with or without nivolumab in metastatic triple-negative breast cancer. Cancer Research, 2022, 82, P2-14-18-P2-14-18.	0.9	1
9	Cardiac outcomes of subjects on adjuvant trastuzumab emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) study (TBCRC033): a randomized controlled trial. Npj Breast Cancer, 2022, 8, 18.	5.2	8
10	Abstract P2-14-17: A phase 1b study of PVX-410 vaccine in combination with pembrolizumab in metastatic triple negative breast cancer (mTNBC). Cancer Research, 2022, 82, P2-14-17-P2-14-17.	0.9	4
11	PARP inhibition in breast cancer: progress made and future hopes. Npj Breast Cancer, 2022, 8, 47.	5.2	42
12	Bilateral Oophorectomy and the Risk of Breast Cancer in BRCA1 Mutation Carriers: A Reappraisal. Cancer Epidemiology Biomarkers and Prevention, 2022, 31, 1351-1358.	2.5	3
13	A prospective trial of treatment de-escalation following neoadjuvant paclitaxel/trastuzumab/pertuzumab in HER2-positive breast cancer. Npj Breast Cancer, 2022, 8, 63.	5.2	18
14	Longitudinal circulating tumor DNA (ctDNA) whole-exome sequencing (WES) in the phase Ib/II trial of palbociclib and bazedoxifene reveals genomic dynamics and clonal evolution with the acquisition of treatment resistance in hormone receptor-positive, HER2-negative (HR+ HER2-), advanced breast cancer (ABC).. Journal of Clinical Oncology, 2022, 40, 1058-1058.	1.6	1
15	Phase 2 study of response-guided neoadjuvant sacituzumab govitecan (IMMU-132) in patients with localized triple-negative breast cancer: Results from the NeoSTAR trial.. Journal of Clinical Oncology, 2022, 40, 512-512.	1.6	22
16	Exploring homologous recombination deficiency thresholds for predicting response to platinum-based treatment in triple negative breast cancer.. Journal of Clinical Oncology, 2022, 40, 525-525.	1.6	0
17	Germline genetic testing in breast cancer: Rationale for the testing of all women diagnosed by the age of 60 years and for riskâ€based testing of those older than 60 years. Cancer, 2021, 127, 828-833.	4.1	20
18	Targeting immunosuppressive macrophages overcomes PARP inhibitor resistance in BRCA1-associated triple-negative breast cancer. Nature Cancer, 2021, 2, 66-82.	13.2	126

#	Article	IF	Citations
19	Breast cancer risk after age 60 amongÂBRCA1 andÂBRCA2 mutation carriers. Breast Cancer Research and Treatment, 2021, 187, 515-523.	2.5	5
20	Survival from breast cancer in women with a BRCA2 mutation by treatment. British Journal of Cancer, 2021, 124, 1524-1532.	6.4	12
21	Limitations of direct-to-consumer (DTC) genetic testing for hereditary breast and ovarian cancer.. Journal of Clinical Oncology, 2021, 39, 10515-10515.	1.6	1
22	A011801 (CompassHER2 RD): Postneoadjuvant T-DM1 + tucatinib/placebo in patients with residual HER2-positive invasive breast cancer.. Journal of Clinical Oncology, 2021, 39, TPS595-TPS595.	1.6	1
23	Patient perspectives on chemotherapy deâ€escalation in breast cancer. Cancer Medicine, 2021, 10, 3288-3298.	2.8	16
24	Twenty-one-gene recurrence score (RS) in germline (g)CHEK2 mutation-associated versus sporadic breast cancers (BC): A multi-site case-control study.. Journal of Clinical Oncology, 2021, 39, 10531-10531.	1.6	0
25	Analysis of real-world (RW) data for metastatic breast cancer (mBC) patients (pts) with somatic BRCA1/2 (sBRCA) or other homologous recombination (HR)-pathway gene mutations (muts) treated with PARP inhibitors (PARPi).. Journal of Clinical Oncology, 2021, 39, 10512-10512.	1.6	1
26	Challenges and Opportunities in Engaging Primary Care Providers in BRCA Testing: Results from the BFOR Study. Journal of General Internal Medicine, 2021, , 1.	2.6	2
27	Chemotherapy-related amenorrhea (CRA) after adjuvant ado-trastuzumab emtansine (T-DM1) compared to paclitaxel in combination with trastuzumab (TH) (TBCRC033: ATEMPT Trial). Breast Cancer Research and Treatment, 2021, 189, 103-110.	2.5	19
28	The predictive ability of the 313 variantâ€“based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variant. Genetics in Medicine, 2021, 23, 1726-1737.	2.4	16
29	A phase II study of efficacy, toxicity, and the potential impact of genomic alterations on response to eribulin mesylate in combination with trastuzumab and pertuzumab in women with human epidermal growth factor receptor 2 (HER2)+ metastatic breast cancer. Breast Cancer Research and Treatment, 2021, 189, 411-423.	2.5	3
30	Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial. Journal of Clinical Oncology, 2021, 39, 2375-2385.	1.6	76
31	Updated Standardized Definitions for Efficacy End Points (STEEP) in Adjuvant Breast Cancer Clinical Trials: STEEP Version 2.0. Journal of Clinical Oncology, 2021, 39, 2720-2731.	1.6	52
32	Phase II trial of veliparib and temozolomide in metastatic breast cancer patients with and without BRCA1/2 mutations. Breast Cancer Research and Treatment, 2021, 189, 641-651.	2.5	16
33	Weight Gain and the Risk of Ovarian Cancer in BRCA1 and BRCA2 Mutation Carriers. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 2038-2043.	2.5	6
34	Germline Genetic Testing for Women With Breast Cancer: Shifting the Paradigm From Whom to Test to Whom NOT to Test. Journal of Clinical Oncology, 2021, 39, 3415-3418.	1.6	9
35	Adjuvant PARP Inhibitors in Patients With High-Risk Early-Stage HER2-Negative Breast Cancer and Germline BRCA Mutations: ASCO Hereditary Breast Cancer Guideline Rapid Recommendation Update. Journal of Clinical Oncology, 2021, 39, 2959-2961.	1.6	34
36	Alliance A011801 (compassHER2 RD): postneoadjuvant T-DM1Â+ tucatinib/placebo in patients with residual HER2-positive invasive breast cancer. Future Oncology, 2021, 17, 4665-4676.	2.4	8

#	Article	IF	Citations
37	Evaluation of TP53 Variants Detected on Peripheral Blood or Saliva Testing: Discerning Germline From Somatic TP53 Variants. JCO Precision Oncology, 2021, 5, 1677-1686.	3.0	7
38	Association of Genomic Domains in BRCA1 and BRCA2 with Prostate Cancer Risk and Aggressiveness. Cancer Research, 2020, 80, 624-638.	0.9	39
39	Pre- and Postoperative Neratinib for HER2-Positive Breast Cancer Brain Metastases: Translational Breast Cancer Research Consortium 022. Clinical Breast Cancer, 2020, 20, 145-151.e2.	2.4	21
40	Patterns of recurrence and metastasis in BRCA1/BRCA2â€associated breast cancers. Cancer, 2020, 126, 271-280.	4.1	74
41	Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes. Nature Genetics, 2020, 52, 56-73.	21.4	120
42	Does preventive oophorectomy increase the risk of depression in BRCA mutation carriers?. Menopause, 2020, 27, 156-161.	2.0	5
43	Association of Tumor-Infiltrating Lymphocytes with Homologous Recombination Deficiency and BRCA1/2 Status in Patients with Early Triple-Negative Breast Cancer: A Pooled Analysis. Clinical Cancer Research, 2020, 26, 2704-2710.	7.0	21
44	A Pre-Testâ€“Post-Test Trial of a Breast Cancer Risk Report for Women in Their 40s. American Journal of Preventive Medicine, 2020, 59, 343-354.	3.0	4
45	Breastfeeding and the risk of epithelial ovarian cancer among women with a BRCA1 or BRCA2 mutation. Gynecologic Oncology, 2020, 159, 820-826.	1.4	10
46	Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants. Genetics in Medicine, 2020, 22, 1653-1666.	2.4	82
47	Reply to S. Takamizawa et al. Journal of Clinical Oncology, 2020, 38, 2700-2701.	1.6	2
48	TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes. Journal of Clinical Oncology, 2020, 38, 4274-4282.	1.6	276
49	Comparison of up-front cash cards and checks as incentives for participation in a clinician survey: a study within a trial. BMC Medical Research Methodology, 2020, 20, 210.	3.1	5
50	Long-term outcomes following a diagnosis of ovarian cancer at the time of preventive oophorectomy among BRCA1 and BRCA2 mutation carriers. International Journal of Gynecological Cancer, 2020, 30, 825-830.	2.5	4
51	Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses. Nature Genetics, 2020, 52, 572-581.	21.4	265
52	Retinoblastoma protein expression and its predictors in triple-negative breast cancer. Npj Breast Cancer, 2020, 6, 19.	5.2	23
53	Adherence to National Comprehensive Cancer Network Guidelines for BRCA testing among high risk breast Cancer patients: a retrospective chart review study. Hereditary Cancer in Clinical Practice, 2020, 18, 13.	1.5	0
54	Characterization of the Cancer Spectrum in Men With GermlineBRCA1andBRCA2Pathogenic Variants. JAMA Oncology, 2020, 6, 1218.	7.1	48

#	Article	IF	Citations
55	Medical Management of newly diagnosed breast cancer in a BRCA1/2 mutation carrier. Breast Journal, 2020, 26, 1506-1512.	1.0	1
56	TBCRC 031: Randomized Phase II Study of Neoadjuvant Cisplatin Versus Doxorubicin-Cyclophosphamide in Germline BRCA Carriers With HER2-Negative Breast Cancer (the INFORM trial). Journal of Clinical Oncology, 2020, 38, 1539-1548.	1.6	88
57	Challenges in Interpreting TP53 Pathogenic Variants With a Low Minor Allele Frequency in Germline Genetic Testing: A Case Report of a Patient With Mosaic Li-Fraumeni Syndrome. JCO Precision Oncology, 2020, 4, 91-95.	3.0	3
58	Transcriptomeâ€wide association study of breast cancer risk by estrogenâ€receptor status. Genetic Epidemiology, 2020, 44, 442-468.	1.3	32
59	Management of Hereditary Breast Cancer: American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Guideline. Journal of Clinical Oncology, 2020, 38, 2080-2106.	1.6	178
60	Factors associated with use of hormone therapy after preventive oophorectomy in BRCA mutation carriers. Menopause, 2020, 27, 1396-1402.	2.0	8
61	860â€...Targeting immunosuppressive macrophages overcomes PARP-inhibitor resistance in BRCA1-associated triple-negative breast cancer. , 2020, , .		1
62	Genetic testing for hereditary breast and ovarian cancer and the USPSTF recommendations. Breast Journal, 2019, 25, 575-577.	1.0	3
63	Patient-reported outcomes in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer receiving olaparib versus chemotherapy in the OlympiAD trial. European Journal of Cancer, 2019, 120, 20-30.	2.8	75
64	Li-Fraumeni syndrome: not a straightforward diagnosis anymoreâ€"the interpretation of pathogenic variants of low allele frequency and the differences between germline PVs, mosaicism, and clonal hematopoiesis. Breast Cancer Research, 2019, 21, 107.	5.0	51
65	When Should Tumor Genomic Profiling Prompt Consideration of Germline Testing?. Journal of Oncology Practice, 2019, 15, 465-473.	2.5	63
66	Shared heritability and functional enrichment across six solid cancers. Nature Communications, 2019, 10, 431.	12.8	88
67	Oestrogen receptor status and survival in women with BRCA2-associated breast cancer. British Journal of Cancer, 2019, 120, 398-403.	6.4	25
68	Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers. British Journal of Cancer, 2019, 121, 180-192.	6.4	19
69	Implications of Neoadjuvant Therapy in Human Epidermal Growth Factor Receptor 2â€"Positive Breast Cancer. Journal of Clinical Oncology, 2019, 37, 2189-2192.	1.6	12
70	BRCA1andBRCA2pathogenic sequence variants in women of African origin or ancestry. Human Mutation, 2019, 40, 1781-1796.	2.5	26
71	Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer. Nature Communications, 2019, 10, 1741.	12.8	90
72	Family communication and patient distress after germline genetic testing in individuals with pancreatic ductal adenocarcinoma. Cancer, 2019, 125, 2488-2496.	4.1	13

#	Article	IF	Citations
73	International trends in the uptake of cancer risk reduction strategies in women with a BRCA1 or BRCA2 mutation. British Journal of Cancer, 2019, 121, 15-21.	6.4	101
74	Oophorectomy and risk of contralateral breast cancer among BRCA1 and BRCA2 mutation carriers. Breast Cancer Research and Treatment, 2019, 175, 443-449.	2.5	12
75	Height and Body Mass Index as Modifiers of Breast Cancer Risk in BRCA1/2 Mutation Carriers: A Mendelian Randomization Study. Journal of the National Cancer Institute, 2019, 111, 350-364.	6.3	30
76	Oncotype DXÂ® Recurrence Score as a Predictor of Response to Neoadjuvant Chemotherapy. Annals of Surgical Oncology, 2019, 26, 366-371.	1.5	76
77	Hormone Replacement Therapy After Oophorectomy and Breast Cancer Risk Among BRCA1 Mutation Carriers. JAMA Oncology, 2018, 4, 1059.	7.1	121
78	Mutational spectrum in a worldwide study of 29,700 families withBRCA1orBRCA2mutations. Human Mutation, 2018, 39, 593-620.	2.5	224
79	Age-specific ovarian cancer risks among women with a BRCA1 or BRCA2 mutation. Gynecologic Oncology, 2018, 150, 85-91.	1.4	65
80	Age at first full-term birth and breast cancer risk in BRCA1 and BRCA2 mutation carriers. Breast Cancer Research and Treatment, 2018, 171, 421-426.	2.5	10
81	A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk. Cancer Research, 2018, 78, 5419-5430.	0.9	54
82	Prospective study of germline genetic testing in incident cases of pancreatic adenocarcinoma. Cancer, 2018, 124, 3520-3527.	4.1	66
83	BRCA1/2 testing: therapeutic implications for breast cancer management. British Journal of Cancer, 2018, 119, 141-152.	6.4	142
84	Challenges in Interpreting Germline Mutations in BARD1 and ATM in Breast and Ovarian Cancer Patients. Breast Journal, 2017, 23, 461-464.	1.0	7
85	Clinical Cancer Advances 2017: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. Journal of Clinical Oncology, 2017, 35, 1341-1367.	1.6	318
86	Managing hereditary breast cancer risk in women with and without ovarian cancer. Gynecologic Oncology, 2017, 146, 205-214.	1.4	16
87	Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation. New England Journal of Medicine, 2017, 377, 523-533.	27.0	2,256
88	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. Nature Genetics, 2017, 49, 680-691.	21.4	356
89	Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. Nature Genetics, 2017, 49, 1767-1778.	21.4	289
90	Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3. Breast Cancer Research and Treatment, 2017, 161, 117-134.	2.5	18

#	Article	IF	Citations
91	Bilateral Oophorectomy and Breast Cancer Risk inBRCA1andBRCA2Mutation Carriers. Journal of the National Cancer Institute, 2017, 109, .	6.3	160
92	Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus. Breast Cancer Research, 2016, 18, 64.	5.0	31
93	Prevalence and predictors of androgen receptor and programmed death-ligand 1 in BRCA1-associated and sporadic triple-negative breast cancer. Npj Breast Cancer, 2016, 2, 16002.	5.2	31
94	Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2. Breast Cancer Research, 2016, 18, 15.	5.0	88
95	Immediate breast reconstruction following mastectomy in pregnant women with breast cancer. Journal of Surgical Oncology, 2016, 114, 140-143.	1.7	18
96	Inheritance of deleterious mutations at both BRCA1 and BRCA2 in an international sample of 32,295 women. Breast Cancer Research, 2016, 18, 112.	5.0	42
97	Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer. Nature Communications, 2016, 7, 11375.	12.8	93
98	Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breastâ€“ovarian cancer susceptibility locus. Nature Communications, 2016, 7, 12675.	12.8	78
99	Counselling framework for moderate-penetrance cancer-susceptibility mutations. Nature Reviews Clinical Oncology, 2016, 13, 581-588.	27.6	258
100	Hormone replacement therapy after menopause and risk of breast cancer in BRCA1 mutation carriers: a caseâ€“control study. Breast Cancer Research and Treatment, 2016, 155, 365-373.	2.5	55
101	Treatment of infertility does not increase the risk of ovarian cancer among women with a BRCA1 or BRCA2 mutation. Fertility and Sterility, 2016, 105, 781-785.	1.0	38
102	The incidence of leukaemia in women with BRCA1 and BRCA2 mutations: an International Prospective Cohort Study. British Journal of Cancer, 2016, 114, 1160-1164.	6.4	24
103	Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer. Clinical Cancer Research, 2016, 22, 3764-3773.	7.0	733
104	Frequency of Germline Mutations in 25 Cancer Susceptibility Genes in a Sequential Series of Patients With Breast Cancer. Journal of Clinical Oncology, 2016, 34, 1460-1468.	1.6	413
105	Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170. Nature Genetics, 2016, 48, 374-386.	21.4	125
106	Perceptions of genetic testing among patients undergoing genetic counseling.. Journal of Clinical Oncology, 2016, 34, e13107-e13107.	1.6	0
107	Distant recurrences in triple negative breast cancer (TNBC) according to androgen receptor (AR) status.. Journal of Clinical Oncology, 2016, 34, 1085-1085.	1.6	0
108	An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers. Breast Cancer Research, 2015, 17, 61.	5.0	26

#	Article	IF	Citations
109	Identification of six new susceptibility loci for invasive epithelial ovarian cancer. Nature Genetics, 2015, 47, 164-171.	21.4	221
110	Effect of Oophorectomy on Survival After Breast Cancer inBRCA1andBRCA2Mutation Carriers. JAMA Oncology, 2015, 1, 306.	7.1	107
111	Association of Type and Location ofBRCA1andBRCA2Mutations With Risk of Breast and Ovarian Cancer. JAMA - Journal of the American Medical Association, 2015, 313, 1347.	7.4	390
112	Tumor-Infiltrating Lymphocytes and Response to Platinum in Triple-Negative Breast Cancer. Journal of Clinical Oncology, 2015, 33, 969-971.	1.6	25
113	Breast cancer screening in the era of density notification legislation: summary of 2014 Massachusetts experience and suggestion of an evidence-based management algorithm by multi-disciplinary expert panel. Breast Cancer Research and Treatment, 2015, 153, 455-464.	2.5	28
114	Clinical Actionability of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Risk Assessment. JAMA Oncology, 2015, 1, 943.	7.1	294
115	Factors influencing ovulation and the risk of ovarian cancer in <scp>BRCA1</scp> and <scp>BRCA2</scp> mutation carriers. International Journal of Cancer, 2015, 137, 1136-1146.	5.1	56
116	Frequency of mutations in individuals with breast cancer referred for <scp>BRCA</scp>1 and <scp>BRCA</scp>2 testing using nextâ€generation sequencing with a 25â€gene panel. Cancer, 2015, 121, 25-33.	4.1	372
117	Prevalence and predictors of androgen receptor (AR) and programmed death-ligand 1 (PD-L1) expression in BRCA1-associated and sporadic triple negative breast cancer (TNBC).. Journal of Clinical Oncology, 2015, 33, 1005-1005.	1.6	2
118	Clinical impact of multi-gene panel testing for hereditary breast and ovarian cancer risk assessment.. Journal of Clinical Oncology, 2015, 33, 1513-1513.	1.6	1
119	Predisposing germline mutations in high grade ER+HER2- breast cancer (BC) patients diagnosed (Dx).. Journal of Clinical Oncology, 2015, 33, 1503-1503.	1.6	0
120	Refined histopathological predictors of BRCA1 and BRCA2mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia. Breast Cancer Research, 2014, 16, 3419.	5.0	97
121	Impact of Oophorectomy on Cancer Incidence and Mortality in Women With a BRCA1 or BRCA2 Mutation. Journal of Clinical Oncology, 2014, 32, 1547-1553.	1.6	523
122	Outcome of triple negative breast cancer: comparison of sporadic and BRCA1-associated cancers. Breast Cancer Research and Treatment, 2014, 146, 175-182.	2.5	21
123	Adjuvant palbociclib (P) plus endocrine therapy (ET) for hormone receptor positive (HR+) breast cancer: A phase II feasibility study.. Journal of Clinical Oncology, 2014, 32, TPS654-TPS654.	1.6	4
124	TBCRC030: A randomized, phase II study of preoperative cisplatin versus paclitaxel in patients (pts) with BRCA1/2-proficient triple-negative breast cancer (TNBC)â€"Evaluating the homologous recombination deficiency (HRD) biomarker.. Journal of Clinical Oncology, 2014, 32, TPS1145-TPS1145.	1.6	1
125	The impact of oophorectomy on survival after breast cancer in BRCA1 and BRCA2 mutation carriers.. Journal of Clinical Oncology, 2014, 32, 1507-1507.	1.6	22
126	A phase II study of eribulin mesylate in combination with trastuzumab and pertuzumab in patients (pts) with metastatic, human epidermal growth factor receptor 2-positive breast cancer.. Journal of Clinical Oncology, 2014, 32, TPS668-TPS668.	1.6	0

#	Article	IF	Citations
127	What Is the Optimal Endocrine Therapy for Postmenopausal Women With Hormone Receptorâ€“Positive Early Breast Cancer?. Journal of Clinical Oncology, 2013, 31, 1391-1397.	1.6	13
128	Should all BRCA1 mutation carriers with stage I breast cancer receive chemotherapy?. Breast Cancer Research and Treatment, 2013, 138, 273-279.	2.5	31
129	Genome-Wide Association Study in BRCA1 Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk. PLoS Genetics, 2013, 9, e1003212.	3.5	244
130	Reply to K. Zaman et al. Journal of Clinical Oncology, 2013, 31, 3441-3441.	1.6	0
131	Immediate tissue expander breast reconstruction following mastectomy in pregnancy-associated breast cancer.. Journal of Clinical Oncology, 2013, 31, 1133-1133.	1.6	0
132	Sentinel lymph node biopsy (SNB) in pregnancy-associated breast cancer (PABC).. Journal of Clinical Oncology, 2013, 31, 1117-1117.	1.6	0
133	Frequency of Triple-Negative Breast Cancer in BRCA1 Mutation Carriers: Comparison Between Common Ashkenazi Jewish and Other Mutations. Journal of Clinical Oncology, 2012, 30, 4447-4448.	1.6	10
134	Evolutionary Pathways in BRCA1-Associated Breast Tumors. Cancer Discovery, 2012, 2, 503-511.	9.4	116
135	Telomeric Allelic Imbalance Indicates Defective DNA Repair and Sensitivity to DNA-Damaging Agents. Cancer Discovery, 2012, 2, 366-375.	9.4	464
136	Pathology of Breast and Ovarian Cancers among BRCA1 and BRCA2 Mutation Carriers: Results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 134-147.	2.5	513
137	Pathologic Features and Immunophenotype of Estrogen Receptorâ€“positive Breast Cancers in BRCA1 Mutation Carriers. American Journal of Surgical Pathology, 2012, 36, 1483-1488.	3.7	11
138	Phase I, open-label study of olaparib plus cisplatin in patients with advanced solid tumors.. Journal of Clinical Oncology, 2012, 30, 1009-1009.	1.6	6
139	Management of Women With BRCA Mutations. JAMA - Journal of the American Medical Association, 2011, 305, 2211.	7.4	27
140	Clinical outcome of triple negative breast cancer in BRCA1 mutation carriers and noncarriers. Cancer, 2011, 117, 3093-3100.	4.1	70
141	Chek2 DNA Damage Response Pathway and Inherited Breast Cancer Risk. Journal of Clinical Oncology, 2011, 29, 3813-3815.	1.6	16
142	Occult ovarian cancers identified at risk-reducing salpingo-oophorectomy in a prospective cohort of BRCA1/2 mutation carriers. Breast Cancer Research and Treatment, 2010, 124, 195-203.	2.5	58
143	Association of Risk-Reducing Surgery in <emph type="ital">BRCA1</emph> or <emph type="ital">BRCA2</emph> Mutation Carriers With Cancer Risk and Mortality. JAMA - Journal of the American Medical Association, 2010, 304, 967.	7.4	1,241
144	Efficacy of Neoadjuvant Cisplatin in Triple-Negative Breast Cancer. Journal of Clinical Oncology, 2010, 28, 1145-1153.	1.6	860

#	Article	IF	Citations
145	Prevalence and predictors of loss of wild type BRCA1 in estrogen receptor positive and negative BRCA1-associated breast cancers. Breast Cancer Research, 2010, 12, R95.	5.0	41
146	Estrogen receptor positive breast cancers in BRCA1 mutation carriers: clinical risk factors and pathologic features. Breast Cancer Research, 2010, 12, R12.	5.0	81
147	Altered Proliferation and Differentiation Properties of Primary Mammary Epithelial Cells from BRCA1 Mutation Carriers. Cancer Research, 2009, 69, 1273-1278.	0.9	63
148	Tamoxifen and contralateral breast cancer inBRCA1 andBRCA2 carriers: An update. International Journal of Cancer, 2006, 118, 2281-2284.	5.1	246
149	Estrogen Receptor Status in BRCA1 - and BRCA2 -Related Breast Cancer. Clinical Cancer Research, 2004, 10, 2029-2034.	7.0	270
150	Contralateral Breast Cancer in BRCA1 and BRCA2 Mutation Carriers. Journal of Clinical Oncology, 2004, 22, 2328-2335.	1.6	595